{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:41:33Z","timestamp":1781660493366,"version":"3.54.5"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"DOI":"10.3389\/fmicb.2019.00019","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T05:16:30Z","timestamp":1548306990000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Injectable Excipients as Novel Influenza Vaccine Adjuvants"],"prefix":"10.3389","volume":"10","author":[{"given":"Huapeng","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago Jose","family":"da Silva Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokiko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4.","volume":"67","author":"Bates","year":"2015","journal-title":"J. Stat. Softw."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.celrep.2015.06.005","article-title":"Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014-2015 influenza season.","volume":"12","author":"Chambers","year":"2015","journal-title":"Cell Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1016\/j.vaccine.2012.09.007","article-title":"Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine.","volume":"30","author":"Das","year":"2012","journal-title":"Vaccine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J. Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1586\/14760584.2016.1142878","article-title":"The effectiveness of influenza vaccination in different groups.","volume":"15","author":"Dominguez","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6527","DOI":"10.1016\/j.vaccine.2010.04.011","article-title":"Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.","volume":"28","author":"Even-Or","year":"2010","journal-title":"Vaccine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"180","DOI":"10.15585\/mmwr.mm6706a2","article-title":"Interim estimates of 2017-18 seasonal influenza vaccine effectiveness - United States, February 2018.","volume":"67","author":"Flannery","year":"2018","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1586\/14760584.2013.811188","article-title":"An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.","volume":"12","author":"Fox","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"B9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1080\/03079450120078707","article-title":"Safety and efficacy of water-in-oil-in-water emulsion vaccines containing Newcastle disease virus haemagglutinin-neuraminidase glycoprotein.","volume":"30","author":"Fukanoki","year":"2001","journal-title":"Avian Pathol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2307\/1593059","article-title":"Relationship between antigen release and antibody response of infectious coryza water-in-oil-in-water emulsion vaccines.","volume":"44","author":"Fukanoki","year":"2000","journal-title":"Avian Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1016\/j.vaccine.2015.04.065","article-title":"Characterization of a novel oil-in-water emulsion adjuvant for swine influenza virus and Mycoplasma hyopneumoniae vaccines.","volume":"33","author":"Galliher-Beckley","year":"2015","journal-title":"Vaccine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1586\/14760584.6.5.723","article-title":"GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives.","volume":"6","author":"Garcon","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"B13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1128\/AEM.16.4.588-594.1968","article-title":"Replication and plaque assay of influenza virus in an established line of canine kidney cells.","volume":"16","author":"Gaush","year":"1968","journal-title":"Appl. Microbiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"56147","DOI":"10.18632\/oncotarget.11269","article-title":"OASIS 2: online application for survival analysis 2 with features for the analysis of maximal lifespan and healthspan in aging research.","volume":"7","author":"Han","year":"2016","journal-title":"Oncotarget"},{"key":"B15","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1128\/IAI.13.6.1559-1562.1976","article-title":"Adjuvant effects of diethylaminoethyl-dextran.","volume":"13","author":"Houston","year":"1976","journal-title":"Infect. Immun."},{"key":"B16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0264-410X(88)90217-4","article-title":"Adjuvant effect of DEAE-dextran on cholera vaccines.","volume":"6","author":"Joo","year":"1988","journal-title":"Vaccine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1016\/j.vaccine.2016.04.001","article-title":"Intranasal hydroxypropyl-beta-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection.","volume":"34","author":"Kusakabe","year":"2016","journal-title":"Vaccine"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v069.i01","article-title":"Least-squares means: the r package lsmeans.","volume":"69","author":"Lenth","year":"2016","journal-title":"J. Stat. Softw."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024384","article-title":"Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines.","volume":"6","author":"Manzoli","year":"2011","journal-title":"PLoS One"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant system AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity.","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033536","article-title":"AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland.","volume":"7","author":"Nohynek","year":"2012","journal-title":"PLoS One"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.4049\/jimmunol.1402027","article-title":"Hydroxypropyl-beta-cyclodextrin spikes local inflammation that induces Th2 cell and T follicular helper cell responses to the coadministered antigen.","volume":"194","author":"Onishi","year":"2015","journal-title":"J. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40264-015-0350-4","article-title":"Comparative safety of vaccine adjuvants: a summary of current evidence and future needs.","volume":"38","author":"Petrovsky","year":"2015","journal-title":"Drug Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.virusres.2011.03.022","article-title":"Mutations in PA, NP, and HA of a pandemic (H1N1) 2009 influenza virus contribute to its adaptation to mice.","volume":"158","author":"Sakabe","year":"2011","journal-title":"Virus Res."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2012.0536","article-title":"Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases.","volume":"10","author":"Shakya","year":"2013","journal-title":"J. R. Soc. Interface"},{"key":"B26","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1159\/000232780","article-title":"Adjuvant effect of nonionic block polymer surfactants in humoral and cellular immunity.","volume":"65","author":"Snippe","year":"1981","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1212\/WNL.0b013e31828ab26f","article-title":"Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination.","volume":"80","author":"Szakacs","year":"2013","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"7658","DOI":"10.1016\/j.vaccine.2012.10.007","article-title":"Adjuvants in influenza vaccines.","volume":"30","author":"Tetsutani","year":"2012","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.1016\/j.vaccine.2014.07.079","article-title":"Hemozoin as a novel adjuvant for inactivated whole virion influenza vaccine.","volume":"32","author":"Uraki","year":"2014","journal-title":"Vaccine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/irv.12383","article-title":"An overview of the regulation of influenza vaccines in the United States.","volume":"10","author":"Weir","year":"2016","journal-title":"Influenza Other Respir. Viruses"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01760","article-title":"AS03- and MF59-adjuvanted influenza vaccines in children.","volume":"8","author":"Wilkins","year":"2017","journal-title":"Front. Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1093\/cid\/ciw635","article-title":"2014-2015 influenza vaccine effectiveness in the United States by vaccine type.","volume":"63","author":"Zimmerman","year":"2016","journal-title":"Clin. Infect. Dis."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2019.00019\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T06:40:27Z","timestamp":1606113627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2019.00019\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,24]]},"references-count":32,"alternative-id":["10.3389\/fmicb.2019.00019"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2019.00019","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,24]]},"article-number":"19"}}